Citius Oncology (CTOR) Return on Capital Employed (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Return on Capital Employed data on file, last reported at 93.55% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 2553.0% year-over-year to 93.55% in Q1 2026; TTM through Mar 2026 was 93.55%, a 2553.0% decrease from a year earlier, with the FY2025 full-year figure at 54.5%, down 957.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 93.55%, down from 36.84% in the prior quarter.
• Over the last five years, Return on Capital Employed for CTOR reached as high as 9.75% in Q4 2023 and fell as low as 93.55% in Q1 2026.
• Historically, Return on Capital Employed has averaged 50.31% across 4 years, with a median of 50.23% in 2025.
• On a YoY basis, Return on Capital Employed climbed as much as 2022 bps in 2025 and fell as far as 5801 bps in 2025.
• Year by year, Return on Capital Employed stood at 9.75% in 2023, then tumbled by 485 bps to 57.06% in 2024, then soared by 35 bps to 36.84% in 2025, then plunged by 154 bps to 93.55% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 93.55% in Q1 2026, 36.84% in Q4 2025, and 50.23% in Q3 2025.